ArticlePituitary2017
Development of ACRODAT
Article in Pituitary, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Questionnaire and tools: clinical powerful instrument in acromegaly diagnosis and management.Journal of endocrinological investigation · 2022Pooled it
- State of the Art of Patient-reported Outcomes in Acromegaly or GH Deficiency: A Systematic Review and Meta-analysis.The Journal of clinical endocrinology and metabolism · 2022Pooled it
- Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: A real-world experience.Pituitary · 2022Trial
- SAGITPituitary · 2025Article
- Factors affecting disease control after pituitary tumor resection in acromegaly: What is the current evidence?World journal of radiology · 2025Article
- ACRODAT and SAGIT for the assessment of disease activity in acromegaly: a multicenter study of the Veneto region in Italy.Pituitary · 2025Article
- Evaluation of fluid status in patients with acromegaly through bioelectrical impedance vector analysis: a cross-sectional study.Journal of endocrinological investigation · 2025Article
- Impact of strict IGF1 control on quality-of-life scores in patients with acromegaly.Frontiers in endocrinology · 2025Article
- Knowledge and attitudes of primary care physicians regarding acromegaly: a survey study with multinational participation.BMC primary care · 2024Article
- Insights from an Italian Delphi panel: exploring resistance to first-generation somatostatin receptor ligands and guiding second-line medical therapies in acromegaly management.Journal of endocrinological investigation · 2024Article
- Article
- Cognition and psychological wellbeing in hypopituitary patients.Reviews in endocrine & metabolic disorders · 2024Review
- Consensus on criteria for acromegaly diagnosis and remission.Pituitary · 2024Article
- Article
- Patient-reported outcomes in refractory hormone-producing pituitary adenomas: an unmet need.Pituitary · 2023Review
- Validation of the anterior skull base questionnaire 35 in endoscopic pituitary adenoma surgery.Neurosurgical review · 2022Article
- Impact of COVID-19 Pandemic on Disease Control Status and Quality of Life of Patients with Acromegaly.Medicina (Kaunas, Lithuania) · 2022Article
- Trabecular Bone Score as a Reliable Measure of Lumbar Spine Bone Microarchitecture in Acromegalic Patients.Journal of clinical medicine · 2022Article
- [Cardiovascular complications associated with acromegaly. A state-of-the-art].Archivos de cardiologia de Mexico · 2022Article
- Evaluation of acromegaly treatment direct costs with respect to biochemical control and follow-up length.Pituitary · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 14 institutions in 10 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDespite availability of multimodal treatment options for acromegaly, achievement of long-term disease control is suboptimal in a significant number of patients. Furthermore, disease control as defined by biochemical normalization may not always show concordance with disease-related symptoms or patient's perceived quality of life. We developed and validated a tool to measure disease activity in acromegaly to support decision-making in clinical practice.
methodsAn international expert panel (n = 10) convened to define the most critical indicators of disease activity. Patient scenarios were constructed based on these chosen parameters. Subsequently, a panel of 21 renowned endocrinologists at pituitary centers (Europe and Canada) categorized each scenario as stable, mild, or significant disease activity in an online validation study.
resultsFrom expert opinion, five parameters emerged as the best overall indicators to evaluate disease activity: insulin-like growth factor I (IGF-I) level, tumor status, presence of comorbidities (cardiovascular disease, diabetes, sleep apnea), symptoms, and health-related quality of life. In the validation study, IGF-I and tumor status became the predominant parameters selected for classification of patients with moderate or severe disease activity. If IGF-I level was ≤1.2x upper limit of normal and tumor size not significantly increased, the remaining three parameters contributed to the decision in a compensatory manner.
conclusionThe validation study underlined IGF-I and tumor status for routine clinical decision-making, whereas patient-oriented outcome measures received less medical attention. An Acromegaly Disease Activity Tool (ACRODAT) is in development that might assist clinicians towards a more holistic approach to patient management in acromegaly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.